Clinical trial
PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma
NCT00240162 · Washington University School of Medicine, Other · Terminated
Key facts
| NCT number | NCT00240162 |
|---|---|
| Title | PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma |
| Official title | A Phase II Study of PTK787/ZK 222584, a Novel, Oral Angiogenesis Inhibitor as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma Following High Dose Chemotherapy and Autologous Stem Cell Transplant |
| Lead sponsor | Washington University School of Medicine, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | PTK787/ZK 222584 |
| Enrollment | 21 |
| Start date | Sep 1, 2005 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Oct 17, 2005 |
| Last update posted | Sep 17, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: